2027 ICD-10-CM Diagnosis Code C79.62Secondary malignant neoplasm of left ovary
ICD-10-CM Codes›C00–D49›C76-C80›C79
- Billable — Valid for Submission
- CC — Complication or Comorbidity
- Risk Adjusts — HCC 18
- Chronic Condition
C79.62 is a billable ICD-10-CM diagnosis code for secondary malignant neoplasm of left ovary. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRG 731 through 733, 754 through 756. As a secondary diagnosis, it counts as a complication or comorbidity (CC) and moves an inpatient stay to a higher severity level within its MS-DRG family. It does not count, however, when the principal diagnosis is one of 23 closely related codes. Coders also document this condition as malignant tumor involving left ovary by direct extension from endometrium. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Secondary malignancies.
For Medicare Advantage risk adjustment, C79.62 maps to CMS-HCC Category 18 (Cancer Metastatic to Bone, Other and Unspecified Metastatic Cancer; Acute Leukemia Except Myeloid) under the V28 model, adding a risk factor of about 2.341 for a community, non-dual, aged beneficiary in payment year 2027.
Code Identity
Code Classification
Medicare Risk Adjustment (HCC)Billing
C79.62 maps to a payment category in the CMS-HCC model used to risk-adjust Medicare Advantage payments. Weights are the published community factors for payment year 2027.
Source: CMS Payment Year 2027 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Malignant tumor involving left ovary by direct extension from endometrium
- Malignant tumor involving left ovary by direct extension from fallopian tube
- Malignant tumor involving left ovary by direct extension from right ovary
- Malignant tumor involving left ovary by direct extension from uterine cervix
- Malignant tumor involving left ovary by direct extension from uterus
- Malignant tumor involving left ovary by direct extension from vagina
- Metastatic malignant neoplasm to left ovary
- Metastatic malignant neoplasm to ovary
- Tumor involves both ovaries diffusely, primary tumor site cannot be determined
Instructional NotesGuidance
Instructions from the official ICD-10-CM Tabular List that apply to C79.62: its own notes plus those printed at C79 and Chapter 2. A note printed at a category, block or chapter applies to every code under it.
Excludes1
Not coded here: the excluded code is never reported together with this one, unless the two conditions are unrelated.
Notes
General instructions on how these codes are used.
- Functional activity
- All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
- Morphology [Histology]
- Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
- Primary malignant neoplasms overlapping site boundaries
- A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
- Malignant neoplasm of ectopic tissue
- Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
Source: CMS ICD-10-CM Tabular List. How to read instructional notes.
Referenced in Other NotesGuidance
Instructional notes printed at other codes that name C79.62, its category, or a range that includes it.
Applicable To 2
These notes mention C79.62.
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Metastatic Malignant Neoplasm in the Ovary
the spread of a malignant neoplasm to the ovary. this may be from a primary ovarian malignant neoplasm involving the opposite ovary, or from a malignant neoplasm at a distant site.
Table of NeoplasmsClinical
Patient EducationClinical
Ovarian Cancer
Cancer is a disease in which abnormal cells in the body grow out of control and form a tumor. Ovarian cancer is a cancerous tumor that forms in the tissues of an ovary. The ovaries are a pair of female reproductive glands that make eggs and female hormones.
The full article covers:
- What is ovarian cancer?
- What are the types of ovarian cancer?
- What causes ovarian cancer?
- Who is more likely to develop ovarian cancer?
- What are the symptoms of ovarian cancer?
- How is ovarian cancer diagnosed?
- What are the treatments for ovarian cancer?
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert C79.62 to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About C79.62Overview
What is the ICD-10 code for secondary malignant neoplasm of left ovary?
The ICD-10-CM code for secondary malignant neoplasm of left ovary is C79.62 (sometimes written as C7962). It is billable on HIPAA-covered claims from October 1, 2026 through September 30, 2027.
Is C79.62 (Secondary malignant neoplasm of ovary) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report secondary malignant neoplasm of left ovary on HIPAA-covered claims from October 1, 2026 through September 30, 2027.
What MS-DRG does C79.62 group to?
When secondary malignant neoplasm of left ovary is the principal diagnosis on an inpatient stay, it groups to MS-DRG 732, 755, 756, 754, 733, 731, with relative weights from 0.8583 to 3.5462 depending on complications. Higher weights mean higher Medicare reimbursement.
Is C79.62 a CC or MCC?
CMS lists C79.62 as a CC (complication or comorbidity) for FY 2027. Reported as a secondary diagnosis, it moves the inpatient stay to a higher-weighted DRG within its severity family. It does not count when the principal diagnosis is one of the 23 closely related codes in its exclusion list.
Can C79.62 be reported with a code from C7B?
Not as a rule. The Excludes1 note at C79, which applies to C79.62, lists "secondary carcinoid tumors (C7B.-)". An Excludes1 note means the excluded code is never reported together with this one; the only exception is when the two conditions are unrelated to each other (Official Guidelines, Section I.A.12.a).
What HCC is C79.62?
C79.62 (secondary malignant neoplasm of left ovary) maps to CMS-HCC Category 18 (Cancer Metastatic to Bone, Other and Unspecified Metastatic Cancer; Acute Leukemia Except Myeloid), commonly written as HCC 18, in the CMS-HCC V28 model used for Medicare Advantage risk adjustment in payment year 2027. It mapped to HCC 8 under the retired V24 model. It also maps in the PACE (CMS-HCC V22), ESRD (V21), and ESRD (V24) models. In the Part D prescription drug model it maps to RxHCC 18.
Does C79.62 risk-adjust for Medicare Advantage payment?
Yes. When documented and reported on a Medicare Advantage encounter, C79.62 adds a risk adjustment factor of about 2.341 to the beneficiary's RAF score for a community, non-dual, aged enrollee (published V28 weights range from 1.110 to 2.537 depending on the payment segment). A more severe related category (HCC 17) supersedes it when both are reported. See the full factor table on the HCC 18 category page.
